SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)*

Aura Biosciences, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value per share

(Title of Class of Securities)

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)
☑ Rule 13d-1(c)
☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Frazier Life Sciences Public Fund, L.P.
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 5,807,260.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 5,807,260.00

9	Aggregate Amount Beneficially Owned by Each Reporting Person 5,807,260.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 5.6 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons FHMLSP, L.P.
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 5,807,260.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 5,807,260.00

9	Aggregate Amount Beneficially Owned by Each Reporting Person

	5,807,260.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 5.6 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons FHMLSP, L.L.C.	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 5,807,260.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 5,807,260.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 5,807,260.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 5.6 %	
12	Type of Reporting Person (See Instructions) OO	

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Frazier Life Sciences X, L.P.	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 128,520.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 128,520.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 128,520.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 0.1 %	
12	Type of Reporting Person (See Instructions) PN	

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons FHMLS X, L.P.
2	Check the appropriate box if a member of a Group (see instructions)

	☐ (a) ☑ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 0.00
	6 Shared Voting Power 128,520.00
	7 Sole Dispositive Power 0.00
	8 Shared Dispositive Power 128,520.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 128,520.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 0.1 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons FHMLS X, L.L.C.
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting	5 Sole Voting Power 0.00
	6 Shared Voting Power 128,520.00
	7 Sole Dispositive Power

Person
With: 0.00

8 Shared Dispositive Power

128,520.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

128,520.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

☐

11 Percent of class represented by amount in row (9)

0.1 %

12 Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

CUSIP No.

1 Names of Reporting Persons

Frazier Life Sciences XI, L.P.

2 Check the appropriate box if a member of a Group (see instructions)

☐ (a)
☑ (b)

3 Sec Use Only

4 Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5 Sole Voting Power

0.00

6 Shared Voting Power

358,810.00

7 Sole Dispositive Power

0.00

8 Shared Dispositive Power

358,810.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

358,810.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

☐

11 Percent of class represented by amount in row (9)

	0.3 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons FHMLS XI, L.P.		
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization DELAWARE		
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00	
	6	Shared Voting Power 358,810.00	
	7	Sole Dispositive Power 0.00	
	8	Shared Dispositive Power 358,810.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 358,810.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐		
11	Percent of class represented by amount in row (9) 0.3 %		
12	Type of Reporting Person (See Instructions) PN		

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons FHMLS XI, L.L.C.
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 358,810.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 358,810.00

9	Aggregate Amount Beneficially Owned by Each Reporting Person 358,810.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 0.3 %
12	Type of Reporting Person (See Instructions) OO

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Frazier Life Sciences XII, L.P.
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 805,410.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 805,410.00

9	Aggregate Amount Beneficially Owned by Each Reporting Person 805,410.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 0.8 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons FHMLS XII, L.P.
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 805,410.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 805,410.00

9	Aggregate Amount Beneficially Owned by Each Reporting Person

	805,410.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 0.8 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons FHMLS XII, L.L.C.	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 805,410.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 805,410.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 805,410.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 0.8 %	
12	Type of Reporting Person (See Instructions) OO	

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons James N. Topper		
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization UNITED STATES		
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00	
	6	Shared Voting Power 128,520.00	
	7	Sole Dispositive Power 0.00	
	8	Shared Dispositive Power 128,520.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 128,520.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐		
11	Percent of class represented by amount in row (9) 0.1 %		
12	Type of Reporting Person (See Instructions) IN		

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Patrick J. Heron
2	Check the appropriate box if a member of a Group (see instructions)

	☐ (a) ☑ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization UNITED STATES		
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00	
	6	Shared Voting Power 128,520.00	
	7	Sole Dispositive Power 0.00	
	8	Shared Dispositive Power 128,520.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 128,520.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐		
11	Percent of class represented by amount in row (9) 0.1 %		
12	Type of Reporting Person (See Instructions) IN		

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 103,436,416 shares of Common Stock outstanding on June 12, 2026, as set forth in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on June 29, 2026.

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Aura Biosciences, Inc.

(b) Address of issuer's principal executive offices:

80 Guest Street, Boston, MA, 02135.

Item 2.

(a) Name of person filing:

The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron" and together with Topper, the "Members")

(b) Address or principal business office or, if none, residence:

The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite 200B Palo Alto, CA 94304

(c) Citizenship:

The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G/A is incorporated by reference.

(d) Title of class of securities:

Common Stock, $0.00001 par value per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) Amount beneficially owned:

The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. FLSPF directly holds 5,807,260 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. FLS X directly holds 128,520 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X. FLS XI directly holds 358,810 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI. FLS XII directly holds 805,410 shares of Common Stock. FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII. The above referenced beneficial ownership and amounts reflected on the cover pages hereto do not include certain prefunded warrants to acquire shares of Common Stock (the "Warrants"), the exercise of which is subject to certain beneficial ownership limitations. In this regard, (i) FLSPF holds Warrants to purchase 1,008,016 shares of Common Stock, (ii) FLS X holds Warrants to purchase 32,130 shares of Common Stock, (iii) FLS XI holds Warrants to purchase 85,552 shares of Common Stock and (iv) FLS XII holds Warrants to purchase 149,302 shares of Common Stock, each of which cannot be exercised, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder of such Warrant (together with its affiliates or any other persons acting as a group together with such holder) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. Except as specifically stated herein, the filing of this Schedule 13G/A shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13G/A or a member of a "group" with any other person.

(b) Percent of class:

The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.

(ii) Shared power to vote or to direct the vote:

The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.

(iii) Sole power to dispose or to direct the disposition of:

The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference.

(iv) Shared power to dispose or to direct the disposition of:

The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences Public Fund, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:	08/14/2026

FHMLSP, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:	08/14/2026

FHMLSP, L.L.C.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:	08/14/2026

Frazier Life Sciences X, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.

Date: 08/14/2026

FHMLS X, L.P.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date: 08/14/2026

FHMLS X, L.L.C.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS X, L.L.C.
Date: 08/14/2026

Frazier Life Sciences XI, L.P.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date: 08/14/2026

FHMLS XI, L.P.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date: 08/14/2026

FHMLS XI, L.L.C.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date: 08/14/2026

Frazier Life Sciences XII, L.P.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date: 08/14/2026

FHMLS XII, L.P.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date: 08/14/2026

FHMLS XII, L.L.C.

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, CFO of FHMLS XII, L.L.C.
Date: 08/14/2026

James N. Topper

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026
Date: 08/14/2026

Patrick J. Heron

Signature: /s/ Jennifer Martin
Name/Title: By Jennifer Martin, Attorney-in-Fact for Patrick

	Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026
Date:	08/14/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G/A filed on February 13, 2026)